@SilasInman

Chief Brand Officer @MJHLifeSciences focused on innovative, audience-driven results @OncLive @MedEconomics @AJMC_Journal @Pharmacy_Times @MDMagazine plus more

 United States
mjhlifesciences.com
Joined August 2011
  • Tweets3.9K
  • Following623
  • Followers818
113Media
FDA Approves Bepirovirsen for Chronic Hepatitis B hcplive.com/view/fda-approve…

FDA Approves Bepirovirsen for Chronic Hepatitis B | HCPLive

FDA approves bepirovirsen after phase 3 trials show 19% achieved functional cure at 24 weeks off all hepatitis B treatment.

hcplive.com
77
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL onclive.com/view/fda-approve…

FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL | OncLive

The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.

onclive.com
53
Adding DLL3×CD3 bispecific tarlatamab to durvalumab maintenance improved OS, PFS, and ORR versus durvalumab alone after platinum/etoposide/durvalumab induction in ES-SCLC onclive.com/view/durvalumab-…

Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance | OncLive

Durvalumab plus tarlatamab significantly improved OS and PFS vs durvalumab alone as maintenance in extensive-stage SCLC, per topline phase 3 data.

onclive.com
1
46
FDA Approves Rusfertide for Polycythemia Vera onclive.com/view/fda-approve…

FDA Approves Rusfertide for Polycythemia Vera | OncLive

The FDA approved rusfertide for the treatment of patients with polycythemia vera.

onclive.com
1
56
FDA Approves Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer cancernetwork.com/view/fda-a…

FDA Approves Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer | CancerNetwork

The FDA has approved daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma based on RASolute 302 trial data.

cancernetwork.com
42
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma onclive.com/view/intismeran-…

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV...

Intismeran autogene plus pembrolizumab improved recurrence-free survival and distant metastasis–free survival in resected stage IIB to IV melanoma.

onclive.com
32
After a positive Ad Comm, the FDA has done a 180 and approves RP1/Nivolumab after progression on anti–PD-1 therapy in Melanoma cancernetwork.com/view/fda-a…

FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma | CancerNetwork

The FDA has approved RP1 plus nivolumab for adults with advanced melanoma who progressed on anti–PD-1 therapy.

cancernetwork.com
83
FDA Approves Orexin Agonist Oveporexton for Narcolepsy Type 1 neurologylive.com/view/fda-a…

FDA Approves Orexin Agonist Oveporexton for Narcolepsy Type 1 | NeurologyLive - Clinical Neurology...

The FDA has approved oveporexton, marketed as Orzeyful, as the first therapy to directly restore orexin signaling and address the full symptom range of narcolepsy type 1.

neurologylive.com
65
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer targetedonc.com/view/fda-acc…

FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer | Targeted Oncology - Immunother...

The NDA for daraxonrasib in PDAC is supported by results from the phase 3 RASolute 302 trial.

targetedonc.com
1
71
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC onclive.com/view/fda-approve… #LCSM

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC | OncLive

The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.

onclive.com
2
91
FDA Approves Enlicitide for LDL-C Lowering in Adults With Hypercholesterolemia hcplive.com/view/fda-approve…

FDA Approves Enlicitide for LDL-C Lowering in Adults With Hypercholesterolemia | HCPLive

FDA approved once-daily oral enlicitide to lower LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

hcplive.com
1
56
Soficitinib (ICP-332) Meets Primary Endpoint in Phase 3 Trial for Moderate to Severe AD dermatologytimes.com/view/so…

Soficitinib (ICP-332) Meets Primary Endpoint in Phase 3 Trial for Moderate to Severe AD | Dermato...

New phase 3 data show oral TYK2 inhibitor soficitinib improves moderate-to-severe atopic dermatitis, easing itch with no new safety signals.

dermatologytimes.com
1
57
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer onclive.com/view/fda-approve…

FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negat...

The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.

onclive.com
1
65
FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for Alzheimer Disease Treatment neurologylive.com/view/fda-a…

FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for...

The approval allows patients to begin lecanemab treatment at home via weekly subcutaneous injection, eliminating the 18-month IV requirement that previously preceded any at-home dosing.

neurologylive.com
1
74
FDA Approves Atacicept (Trutakna) for IgA Nephropathy hcplive.com/view/fda-approve…

FDA Approves Atacicept (Trutakna) for IgA Nephropathy | HCPLive

The FDA granted accelerated approval to atacicept to reduce proteinuria in adults with primary IgAN at risk for disease progression

hcplive.com
2
655
Namodenoson Yields Durable Survival Outcomes in Pretreated Pancreatic Cancer cancernetwork.com/view/namod…

Namodenoson Yields Durable Survival Outcomes in Pretreated Pancreatic Cancer | CancerNetwork

Updated phase 2a data showed durable survival in a small subset of heavily pretreated patients with advanced pancreatic cancer treated with namodenoson.

cancernetwork.com
29
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC onclive.com/view/fda-approve…

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC | OncLive

The FDA approved capivasertib plus abiraterone and prednisone for PTEN-deficient metastatic androgen pathway modulation–naive or sensitive prostate cancer.

onclive.com
29
AZ is joining the GLP1 market: Elecoglipron Advances to Phase 3, Shows Phase 2 Weight Loss, Glycemic Data hcplive.com/view/elecoglipro…

Elecoglipron Advances to Phase 3, Shows Phase 2 Weight Loss, Glycemic Data | HCPLive

Elecoglipron 75 mg produced 10.5% body weight reduction at 26 weeks in VISTA and a 1.9% HbA1c reduction at 26 weeks in SOLSTICE.

hcplive.com
1
35
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer onclive.com/view/vopimetosta…

Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer |...

Phase 1/2 data show that the PRMT5 inhibitor vopimetostat plus daraxonrasib yielded a 92% ORR in MTAP-deleted, RAS-mutant metastatic pancreatic cancer.

onclive.com
1
50
A near miss in colorectal cancer. #ASCO26: JCOG’s EPISODE-III found low-dose aspirin fell just short on DFS in unselected stage III CRC (HR 0.84, p=0.099). The +3.4% 3Y-DFS signal and RFS trend (HR 0.87) suggest the answer may live in the biomarkers. PI3K/PIK3CA analyses ongoing.
1
75
Load more